| Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.Fertil Steril | PMID 33814126无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.J Urol | PMID 33818140无 PMCID | 2021-Aug | 0.85 | The record describes an indirect comparison (network meta-analysis) of multiple prior trials, not an original primary or key secondary report of a single randomized trial. The primary efficacy endpoint (metastasis-free survival) is a time-to-event outcome, but the analysis is a post-hoc adjusted comparison. The drug intervention is not clearly established as a single drug-containing arm within a trial being reported; the study compares multiple drugs across separate trials. | 待处理 |
| Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.Ann Rheum Dis | PMID 33827787PMC8292606 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.J Thorac Oncol | PMID 33845211无 PMCID | 2021-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future Oncol | PMID 33855868PMC9344436 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.Future Oncol | PMID 33858190无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.Cephalalgia | PMID 33874756无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.Diabetes Obes Metab | PMID 33881796无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.Clin Trials | PMID 33884929PMC8290982 | 2021-Aug | 0.90 | The study is a randomized phase 3 drug trial in oncology, but it evaluates pain measurement methodology as the primary endpoint, not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria for inclusion in the cohort. | 待处理 |
| Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.Breast | PMID 33892316PMC8091175 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.Ann Rheum Dis | PMID 33906853PMC8292568 | 2021-Aug | 0.90 | Study is a Phase III randomized drug trial with original results, but it is not an oncology study (ankylosing spondylitis) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) as required for this oncology KM-digitization cohort. | 待处理 |
| Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.J Thorac Oncol | PMID 33915252无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.Ann Oncol | PMID 33932507无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinicaltrial.Int Immunopharmacol | PMID 33933848无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.Pediatr Diabetes | PMID 33934456PMC8361970 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).Ann Rheum Dis | PMID 33958326PMC8292566 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.Acta Orthop | PMID 33977825PMC8382018 | 2021-Aug | 0.85 | The record describes a Phase III randomized clinical trial of a drug (pexidartinib) for tenosynovial giant cell tumor (oncology). However, the primary/key efficacy endpoints reported are patient-reported outcomes (physical function and stiffness), not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.Gynecol Oncol | PMID 34016453无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.Epilepsy Behav | PMID 34023810无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.Oncologist | PMID 34028126PMC8342591 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer Sci | PMID 34036692PMC8353942 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.Br J Haematol | PMID 34046887无 PMCID | 2021-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.Lancet Respir Med | PMID 34051877PMC8159193 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.Respir Med | PMID 34058682无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 34087115无 PMCID | 2021-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns.Burns | PMID 34099322无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.Ann Oncol | PMID 34102253无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.Mol Cancer Ther | PMID 34108261无 PMCID | 2021-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.Gynecol Oncol | PMID 34112513无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.Dig Liver Dis | PMID 34112615无 PMCID | 2021-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.Neurourol Urodyn | PMID 34139038PMC8362047 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.Breast Cancer Res Treat | PMID 34148205PMC8272708 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.Lancet Gastroenterol Hepatol | PMID 34153231无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a live attenuated varicella vaccine in children 1-12 years of age: A randomized, blinded, controlled, non-inferiority phase 3 clinical trial.Contemp Clin Trials | PMID 34157417无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.Br J Cancer | PMID 34158598PMC8405616 | 2021-Aug | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 34174189无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Senior WISE intervention: Gender differences in bodily pain and trait anxiety.Arch Psychiatr Nurs | PMID 34176575PMC8239252 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.Cancer Med | PMID 34189869PMC8366100 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.Ann Oncol | PMID 34219000无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase II/III placebo-controlled randomized trial of safety and efficacy of growth hormone treatment in incomplete chronic traumatic spinal cord injury.Spinal Cord | PMID 34226654无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.Aliment Pharmacol Ther | PMID 34227708PMC8361733 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 34237250无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.Lancet Oncol | PMID 34252374无 PMCID | 2021-Aug | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.Eur J Cancer | PMID 34256319无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| [Not Available].Aktuelle Urol | PMID 34318458无 PMCID | 2021-Aug | 0.45 | Metadata confirms oncology, human, randomized, Phase III. However, the abstract is empty and deterministic review found no reliable time-to-event signal or drug intervention signal. Cannot establish eligibility without explicit confirmation of a drug-containing intervention and a primary/key secondary time-to-event endpoint from the original report. | 待处理 |
| Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study.Clin Ther | PMID 34332788无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.EBioMedicine | PMID 34333237PMC8340125 | 2021-Aug | 0.70 | The record is eligible for oncology, human, randomized, phase 3, and time-to-event, but the drug intervention is not explicitly described or evaluated in this report (it's a biomarker sub-study). Therefore, it does not meet the inclusion criteria for a primary drug-efficacy report. | 待处理 |
| Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.ESMO Open | PMID 34371381PMC8358416 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Practice nurse-supported weight self-management delivered within the national child immunisation programme for postnatal women: a feasibility cluster RCT.Health Technol Assess | PMID 34382932无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.RMD Open | PMID 34385364PMC8362717 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |